β-Interferon, Human, Recombinant, CHO Cells

Recombinant, human interferon-β (IFN-β) expressed in CHO cells as a single glycosylated polypeptide containing 166 amino acids. Purified by chromatographic methods. IFN-β is a type I cytokine produced in response to exposure to viruses or double-stranded RNAs. It is also induced by other cytokines, such as TNF and IL-1. It is involved in the regulation of non-specific humoral immune responses and immune responses to viral infections, and thus exhibits anti-viral, anti-proliferative, and immunomodulating properties. The biological activity of IFN-β, unlike IFN-α, is strictly species-specific and will not be active across species.

Recombinant, human interferon-β (IFN-β) expressed in CHO cells as a single glycosylated polypeptide containing 166 amino acids. Purified by chromatographic methods. IFN-β is a type I cytokine produced in response to exposure to viruses or double-stranded RNAs. It is also induced by other cytokines, such as TNF and IL-1. It is involved in the regulation of non-specific humoral immune responses and immune responses to viral infections, and thus exhibits anti-viral, anti-proliferative, and immunomodulating properties. The biological activity of IFN-β, unlike IFN-α, is strictly species-specific and will not be active across species.

Reported as IU/mg on a lot-specific basis using a viral resistance assay

Toxicity: Standard Handling (A)

Lyophilized from 62 mg/ml mannitol, 9.1 mg/ml human albumin, 0.9 mg/ml acetate, pH 7.0-7.2.

Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 7 days at 4°C or for up to 4 months at -20°C. Avoid freeze/thaw cycles of solutions.

Reconstitute with sterile water to ≥100 µg/ml, containing 0.1% HSA or BSA. Further dilute with aqueous buffer just prior to use.

Goebel, M.U., et al. 2005. Physiol. Behav.84, 807.
Graber, J., et al. 2005. J. Neuroimmunol.161,169.
Mallada-Frechin, J., et al. 2005. Rev. Neurol.40, 482.
Patten, S.B., et al. 2005. Mult. Scler.11, 175.
Pohl, D., et al. 2005. Neurology64, 888.
Schwid, S.R., et al. 2005. Arch. Neurol.62, 785.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany